New York . There is an increased risk of developing a very rare blood-clotting condition called thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the COVID-19 virus. This is revealed in a new research. According to the researchers, TTS occurs when a person has a low blood platelet count (thrombocytopenia) along with a blood clot (thrombosis).

This is very rare and is different from common clotting conditions, such as deep vein thrombosis (DVT) or a lung clot (pulmonary embolism). This syndrome is currently being investigated as a rare side effect of adenovirus-based COVID-19 vaccines, which use a weakened virus to trigger an immune response against the coronavirus, but there is no information on the comparative safety of the different types of vaccines. Clear evidence does not exist.

For the study, published in the British Medical Journal (BMJ), the researchers stressed that the syndrome is very rare, but that these risks should be considered when planning further vaccination campaigns and future vaccine development.

Based on health data from five European countries and the US, it shows a small increased risk of TTS after the first dose of the Oxford-AstraZeneca vaccine, and an increased risk of TTS after the Janssen/Johnson & Johnson vaccine. Shows a trend towards risk.

However, this was a well-designed study that compared available vaccines with no immunizations with each other, and the results were consistent after additional analysis.

–IANS

read this also – Click to read the news of your state / city before the newspaper